Analysts expect Core Laboratories (NYSE:CLB) to announce earnings of $0.58 per share for the current quarter, Zacks reports. Two analysts have provided estimates for Core Laboratories’ earnings. Core Laboratories posted earnings of $0.41 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.5%. The business is scheduled to report its next earnings results after the market closes on Wednesday, January 31st.

According to Zacks, analysts expect that Core Laboratories will report full year earnings of $1.99 per share for the current financial year, with EPS estimates ranging from $1.95 to $2.00. For the next financial year, analysts forecast that the firm will report earnings of $2.70 per share, with EPS estimates ranging from $2.42 to $2.92. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Core Laboratories.

Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Monday, October 23rd. The oil and gas company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.04. Core Laboratories had a return on equity of 52.89% and a net margin of 12.06%. The firm had revenue of $166.20 million for the quarter, compared to analyst estimates of $160.94 million. During the same quarter in the previous year, the company posted $0.38 EPS. The business’s revenue was up 1.4% on a year-over-year basis.

A number of research firms have commented on CLB. Deutsche Bank lowered Core Laboratories from a “buy” rating to a “hold” rating and reduced their price target for the company from $116.30 to $109.00 in a research report on Thursday, January 11th. ABN Amro downgraded Core Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Royal Bank of Canada set a $110.00 price objective on Core Laboratories and gave the company a “buy” rating in a research note on Thursday, December 21st. Loop Capital set a $115.00 price objective on Core Laboratories and gave the company a “buy” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research downgraded Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $110.20.

Several large investors have recently made changes to their positions in CLB. Schwab Charles Investment Management Inc. lifted its stake in shares of Core Laboratories by 6.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 139,549 shares of the oil and gas company’s stock valued at $14,133,000 after purchasing an additional 8,774 shares during the period. CIBC World Markets Inc. acquired a new position in Core Laboratories during the 2nd quarter worth approximately $223,000. Eaton Vance Management raised its stake in Core Laboratories by 46.4% during the 2nd quarter. Eaton Vance Management now owns 21,852 shares of the oil and gas company’s stock worth $2,213,000 after buying an additional 6,924 shares during the period. Alliancebernstein L.P. raised its stake in Core Laboratories by 18.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,942 shares of the oil and gas company’s stock worth $298,000 after buying an additional 448 shares during the period. Finally, Nationwide Fund Advisors raised its stake in Core Laboratories by 27.6% during the 2nd quarter. Nationwide Fund Advisors now owns 7,881 shares of the oil and gas company’s stock worth $798,000 after buying an additional 1,705 shares during the period.

Core Laboratories (CLB) traded up $0.11 during midday trading on Tuesday, hitting $119.10. The company’s stock had a trading volume of 318,200 shares, compared to its average volume of 433,022. Core Laboratories has a 1 year low of $86.55 and a 1 year high of $124.99. The company has a market cap of $5,200.00, a price-to-earnings ratio of 68.84 and a beta of 1.56. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.18 and a quick ratio of 1.81.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/16/0-58-earnings-per-share-expected-for-core-laboratories-clb-this-quarter.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Get a free copy of the Zacks research report on Core Laboratories (CLB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.